



**Oncidium
foundation**

Access • Education • Hope



**Support, promote & accelerate the development of
radiotheranostics for cancer care worldwide**

Recent research and development has brought forward the pivotal role of radiotheranostics for cancer care. Whether you refer to them as radiotheranostics, theranostics, theragnostics, radioligand therapy, peptide receptor radioligand therapy (PRRT), radiopharmaceuticals or radionuclide therapy, they all describe an innovative approach to cancer care through the beneficial application of radioisotopes, within the nuclear medicine field.

As a recent approach in cancer diagnosis and therapy, there is still a lot to do to bring forward the availability and potential of the technology. The Oncidium foundation endeavors, on a daily basis, to raise awareness about radiotheranostics as alternatives for cancer care and **to provide support to accelerate global access.**

Richard Zimmermann,
Tala Allahham, Rebecca Loebue, Floriane Laurent

WHO ARE WE?

“ We are motivated to help people to live longer and better lives. Patients are the core focus of the foundation, notably through the daily efforts that are put into accelerating global access to radiotheranostics for cancer care. ”

Rebecca Loebue, General Manager

“ Progresses made in radionuclide theranostics over the last years have shown incredible results. My main wish with this new team is to make this technology available for the largest number of people living with cancer. ”

Richard Zimmermann
Founder & President
The Oncidium foundation



The Oncidium foundation team is fully dedicated to supporting and advancing the development of nuclear medicine therapies considering that many patients and non-nuclear practitioners are still unaware of the existence and benefits of radiotherapeutics, and that there is still a lot to do to bring forward this option in the cancer care landscape.

As a non-profit and public benefit organization, the Oncidium foundation is independent. Thus, solely focusing on reaching out to patients and other interlocutors and on providing accurate information about the existence and potential benefits of this innovative technology.

ADVANCING RADIO-THERANOSTICS **ACCESS**

The Oncidium foundation endeavors to make radiotherapeutics available for as many people as possible. Therefore, efforts are concentrated towards improving patient access to cancer treatments and clinical trials.

An effective platform is available on our website for:

- **PATIENTS** to find the nearest treatment center, current clinical trials & to facilitate communication with medical experts
- **PRACTITIONERS** to consider and include radiotheranostics as an option for cancer care
- **EXPERTS IN RADIOTHERAPEUTICS** to support precision medicine and its progresses.

Register your hospital on our global directory 



Help cancer patients find the nearest therapy center more easily and make radiotheranostics-based therapies more accessible.

To register your center: www.oncidiumfoundation.org/register

ADVANCING RADIO-THERANOSTICS **EDUCATION**

The Oncidium foundation is a worldwide hub connecting patients, practitioners and experts in the nuclear medicine field.

Education and Awareness are key to support the development of personalized medicine, as it helps to bring a better understanding of the functioning and benefits of radiotherapeutics for cancer care.

Education is focused on:

- **PATIENTS:** by explaining how radiotherapeutics work and can sometimes be an effective option for cancer treatments
- **PRACTITIONERS:** by helping them to take note and keep track of rapidly increasing developments around radiotheranostics.

Did you know?

The Oncidium foundation aims to provide accurate and updated information about all you need to know regarding radionuclides and radiopharmaceuticals, notably through an **extensive and collaborative list of radiotherapeutics for cancer care.**

Wish to learn more or to suggest a missing molecule? Visit our website:

www.oncidiumfoundation.org/education



More about education and awareness?

Visit our YouTube channel:
www.youtube.com/@oncidiumfoundation9833



ADVANCING RADIO- THERANOSTICS **HOPE**



The Oncidium foundation is driven by the long-term vision of improving lives globally. Common efforts and working hand in hand are essential to provide hope:

- for **patients**, when other options have failed
- for **patients**, that are not able to afford the therapy costs
- by supporting projects and research to further develop radiotheranostics availability and access, globally.

Interested to support our projects or to collaborate?

Contact us:
contact@oncidium-life.org



Every man deserves access to adequate prostate cancer diagnostic imaging

The NOBLE Registry is an international clinical collaboration supported by Telix Pharmaceuticals and the Oncidium foundation for the development of ^{99m}Tc-iPSMA SPECT imaging¹.

PET technologies are rapidly gaining popularity with their high accuracy to detect prostate cancer recurrence and metastases. However, PET scans are scarce in some parts of the world and imaging products may come at a high cost and require adapted facilities.

The NOBLE Registry is dedicated to developing an efficient and affordable alternative through SPECT-imaging.


The aim is to enable people living with prostate cancer - regardless of origin, technology availability or financial situation - to access PSMA-SPECT imaging, ultimately providing accurate diagnosis and further treatment planning with the associated therapeutic agent based on the same vector.

More information on: nobleregistry.org

¹ ^{99m}Tc-iPSMA is authorized for investigational use only.

RADIOTHERANOSTICS: HOW DOES IT WORK?

Radiopharmaceuticals are molecules developed as diagnostic and/or therapeutic agents based on drugs labeled with radioactive substances and injected as a drug to patients. When these molecules are developed as pairs for diagnosis and therapy in the same disease, they are called radiotheranostic pairs.



What's what?

- For each pathology, specific ligands can be associated with receptors from the targeted cells
- This ligand can be converted in a vector that will carry a radioactive atom (radioisotope) to this target.

Use?

Depending on the type of emitted radiation (rays or particles) the radioactive substance (radionuclide) will act as:

- a tracer, i.e. an imaging (diagnosis) agent emitting a signal from the targeted cell that is detected by a scanner and will create images **OR**
- a drug, i.e. a therapeutic agent destroying the targeted cells.

Its role?

Precisely target a biological entity that is specific for one tissue, one type of cell or one organ (e.g. a tumor cell).

Watch our
animated videos



SUCCESS STORY

In the battle against metastatic prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (¹⁷⁷Lu).

The images below come from a research team at the Peter MacCallum Cancer Centre in Melbourne, Australia.

They demonstrate exceptional responses in a series of patients who received ¹⁷⁷Lu-PSMA therapy after other treatments stopped working. In each patient, the extent of tumor spread before and after treatment is visualized with clarity using PSMA PET.

These patients experienced improved quality of life, including reduction of pain correlated with marked reduction of prostate specific antigen (PSA), a blood tumor marker.





Image used with permission of Prof. Michael Hofman, Peter MacCallum Cancer Centre, Melbourne, Australia

TOM & FERNANDO

Tom Bajoras is a composer, pianist, audio producer and neuroendocrine tumor (NETs) patient

When he was diagnosed with NETs, he didn't know that PRRT could save his life. In this testimonial, Tom shared his journey and battle against a pancreatic tumor. His insight and wisdom can provide clarity and hope to those who are just beginning their treatment journey or are uncertain about the realities of treatment.

"I'm a big fan of theranostics, it saved my life. I would love for other people to know about PRRT as a treatment option, not be afraid of it and get more access to it."



April 2016

January 2017

Dr. Fernando Acosta, husband, father, grandfather, war veteran and doctor: his journey living with prostate cancer

"At the age of 55, in apparent perfect



health and with 21 years of professional practice, I was diagnosed with a Paraneoplastic Syndrome, behind which was hidden an advanced Prostate Adenocarcinoma Gleason 9, non-surgical.

in a few days, the scientist behind this treatment, the radiochemist who prepares the medication in Argentina, and the lawyers who, together with the reasoning of a judge, made the impossible possible.

I focused and visualized lutetium diagnosing, irradiating, and eliminating every neoplastic cell in my body. After three doses and observing the scans using gamma camera and the last PET PSMA without evidence of neoplastic focus in activity, tears of happiness ran on my cheeks and on all of those who believed in me and helped unconditionally.

In 4 years and after 42 sessions of chemotherapy every 21 days, a protocol for 3 months that did not work, and radiotherapy, there was nothing left to try but to continue with more chemotherapy.

When I found out about the Lutetium treatment, I did not care that it was impossible. I gathered 70000 signatures

Today I lead a group of patients with prostate cancer in treatment with lutetium. I am eternally grateful to the scientists who discovered the usefulness of this radionuclide, to the Oncidium foundation and to my treating physician Dr. María Bastianello whose humanity and dedication surprises me every day."

AMBASSADORS

The foundation is composed of a wide network of Ambassadors from all around the world.

These theranostics experts and enthusiasts exchange ideas, share their projects, visions, and aspirations for the work of the foundation locally and internationally, to further support the development of radiotheranostics for cancer care.



Working beyond borders

To reach a common goal, Ambassadors' missions include:

- **Spreading the word about radiotheranostics** and representing the foundation in local and international events
- **Breaking barriers at a national level** to enhance radiotheranostics access
- **Enhancing the Oncidium foundation community** and enrolling other nuclear medicine experts in the life of the foundation
- **Building collaborations and partnerships** with key players in the field
- **Suggesting initiatives and projects** for the benefit of patients
- **Updating the foundation about radiotheranostics matters** such as medical breakthroughs, ongoing clinical trials, etc.
- **Writing, reviewing, translating and sharing** content produced by the foundation
- **Creating a local Oncidium foundation structure.**



Interested to join our international network?

Contact@oncidium-life.org

Aims of the foundation:

- Enhance patient access
- Accelerate clinical developments
- Improve production capacities
- Support early-stage developments
- Increase partnerships



sck cen



CHRYSLIUM
CONSULTING

The
Health Policy
Partnership
[research, people, action]



ZERO Biotech



PET RADIOPHARMACEUTICALS
Molecular Imaging



Contact us:

The Oncidium foundation
Avenue Herrmann-Debroux, 40
1160 Brussels | Belgium
www.oncidiumfoundation.org
contact@oncidium-life.org

Join our community...

- Become an Ambassador
- Register your therapy center
- Trust us with your projects

... and spread the word!

